Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U4 small nuclear 60, pseudogene (RNU4-60P) is annotated as a pseudogene presumed to be related to U4 small nuclear RNA (snRNA) gene family, which produces structural RNAs critical for pre-mRNA splicing as part of the spliceosome in humans. However, pseudogenes are generally defined as genomic DNA sequences similar to normal genes but non-functional; they are usually not transcribed or translated into functional products. RNU4-60P lacks evidence of encoding a functional RNA molecule, and no data indicate biological activity, disease association, or a role as a therapeutic target. This distinguishes RNU4-60P from functional homologues like RNU4-2, which is essential for major spliceosome assembly and human neurodevelopment[1][2][3][5]. No evidence indicates that RNU4-60P serves as a therapeutic target, biomarker, or is the subject of drug development. ### Notes - The "RNU4-60P" gene is a **pseudogene**, not an active target molecule. Functional disease associations, biological activities, or pharmacological targeting as described for RNU4-2 do **not apply** to pseudogenes unless otherwise shown by experimental evidence (not found for RNU4-60P in the search results). - There are other U4 snRNA genes (e.g., "RNU4-2") with clear roles in splicing and disease[1][2][3][5], but RNU4-60P is not one of them and should not be confused as a functional target. - The query likely refers to a **non-protein-coding pseudogene**, not a druggable or biologically active entity. **In summary: RNU4-60P is a pseudogene (inactive copy) related to U4 snRNA, not a functional therapeutic target, and contains no reported biological function, disease role, or drug interaction.**
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 60, pseudogene (RNU4-60P).